The 1691 G → A mutation in the factor V gene: Relationship to activated protein C (APC) resistance and thrombosis in 65 patients

Thrombosis and Haemostasis

Volumn 75, Issue 1, 1996, Pages 4-10

  Leroy Matheron, Catherine ^a   Levent, Martine ^a   Pignon, Jean Michel ^a   Mendonça, Caio ^a   Gouault Heilmann, Michèle ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; FIBRINOGEN DEGRADATION PRODUCT; PROTHROMBIN; THROMBIN; ADENINE; FIBRINOLYTIC AGENT; GUANINE; PROTEIN C;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; FAMILY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PREVALENCE; PRIORITY JOURNAL; THROMBOSIS; ADOLESCENT; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE;

ADENINE; ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DRUG RESISTANCE; FACTOR V; FEMALE; FIBRINOLYTIC AGENTS; GUANINE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE; PROTEIN C; THROMBOSIS;

EID: 0029670609     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650212     Document Type: Article

References (34)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. The Lancet 1993; 342: 1503-6.
3. Aillaud MF, Succo E, Alhenc-Gelas M, Gandrille S, Brunet D, Pouymayou K, Alessi MC, Aiach M, Juhan-Vague I. Résistance à la protéine C activée (RPCA) : étude prospective sur 6 mois. Proc Congr Angio Genève 1994, 113 (abstract).
4. Trossaërt M, Conard J, Horellou MH, Elalamy I, Samama MM. Prévalence de la résistance à la protéine C activée chez 175 patients ayant des antécédents thromboemboliques veineux. Proc Congr Angio Genève 1994; 114 (abstract).
5. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
6. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
7. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-22.
8. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci 1994; 91: 1396-400.
9. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-5.
10. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Rettsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
11. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagulation and Fibrinolysis 1995; 6: 245-7.
12. Amiral J, Grosley B, Boyer-Neumann C, Marfaing-Koka A, Peynaud-Debayle E, Wolf M, Meyer D. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagulation and Fibrinolysis 1994; 5: 179-86.
13. Wolf M, Boyer-Neumann C, Martinolli JL, Leroy-Matheron C, Amiral J, Meyer D, Larrieu MJ. A new functional assay for human protein S activity using activated factor Va as substrate. Thromb Haemost 1989; 62: 1144-5.
14. Nicham F, Guichaoua JF, Contant G, Martinoli JL. Dosage rapide de l'activité de la protéine C. Ann Biol Clin 1986; 46: 805-9.
15. Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 1986; 43: 253-64.
16. Ødegard OR, Lie M, Abilgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-94.
17. Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9
18. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
19. Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Fiessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-6.
20. Stirling D, White A, Clarkson J, Stewart A, Ludlam CA. A comparison between functional and genetic testing for activated protein C resistance (APCR). Blood Coagulation and Fibrinolysis 1995; 6: 154 (abstract).
21. Vooerberg J, Roelse J, Koopman R, Büller H, Berends F, Ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
22. Borg JY, Beufé S, Vasse M, Monconduit M, Frébourg T. Relations risque thrombotique - phénotype - génotype dans une grande famille avec facteur V Leiden. Proc Congr Angio Genève 1994: 106 (abstract).
23. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
24. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report : variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gln mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-62.
25. Scarano L, Simioni P, Gavasso S, Sardella C, Rossi L, Scudeller A, Girolami A. F1+2 and TAT levels in patients with inherited APC-resistance. Thromb Haemost 1995; 73: 1366 (abstract).
26. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of factor V from APC-resistant patients homozygous for the Arg 506 → Gln mutation. Thromb Haemost 1995; 73: 1362 (abstract).
27. Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Int Med 1987; 106: 677-82.
28. Gouault-Heilmann M, Leroy-Matheron C, Levent M. Inherited protein S deficiency: clinical manifestations and laboratory findings in 63 patients. Thromb Res 1994; 76: 269-79.
29. Broekmans AW, Conard J. Hereditary protein C deficiency. In: Protein C and Related Proteins. Bertina RM. eds. Churchill. Livingstone, 1988; pp160-81.
30. Van der Bom JG, Kluft C, Bots ML, Haverkate F, Slagboom E, Meijer P, Grobbee DE. Factor V mutation, APC resistance and myocardial infarction in the Rotterdam study. Thromb Haemost 1995; 73: 1373 (abstract).
31. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction is not associated with the Arg 506 to Gln factor V mutation causing resistance to activated protein C. Thromb Haemost 1995; 73: 1373 (abstract).
32. Seligsohn U, Berger A, Abend M. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-62.
33. Mahasandana C, Suvatte V, Chuansumrit A, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediat 1990; 117: 750-3.
34. Heeb MJ, Mesters RM, Tans G, Rosing J , Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.